1. Home
  2. ANAB vs DDL Comparison

ANAB vs DDL Comparison

Compare ANAB & DDL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ANAB
  • DDL
  • Stock Information
  • Founded
  • ANAB 2005
  • DDL 2014
  • Country
  • ANAB United States
  • DDL China
  • Employees
  • ANAB N/A
  • DDL N/A
  • Industry
  • ANAB Biotechnology: Pharmaceutical Preparations
  • DDL Catalog/Specialty Distribution
  • Sector
  • ANAB Health Care
  • DDL Consumer Discretionary
  • Exchange
  • ANAB Nasdaq
  • DDL Nasdaq
  • Market Cap
  • ANAB 759.5M
  • DDL 666.1M
  • IPO Year
  • ANAB 2017
  • DDL 2021
  • Fundamental
  • Price
  • ANAB $20.55
  • DDL $2.20
  • Analyst Decision
  • ANAB Buy
  • DDL
  • Analyst Count
  • ANAB 10
  • DDL 0
  • Target Price
  • ANAB $36.38
  • DDL N/A
  • AVG Volume (30 Days)
  • ANAB 1.0M
  • DDL 963.3K
  • Earning Date
  • ANAB 05-08-2025
  • DDL 05-12-2025
  • Dividend Yield
  • ANAB N/A
  • DDL N/A
  • EPS Growth
  • ANAB N/A
  • DDL N/A
  • EPS
  • ANAB N/A
  • DDL 0.13
  • Revenue
  • ANAB $91,280,000.00
  • DDL $3,158,412,712.00
  • Revenue This Year
  • ANAB N/A
  • DDL $17.17
  • Revenue Next Year
  • ANAB $37.76
  • DDL $9.74
  • P/E Ratio
  • ANAB N/A
  • DDL $16.85
  • Revenue Growth
  • ANAB 432.03
  • DDL 4.61
  • 52 Week Low
  • ANAB $12.21
  • DDL $1.08
  • 52 Week High
  • ANAB $41.31
  • DDL $4.79
  • Technical
  • Relative Strength Index (RSI)
  • ANAB 65.12
  • DDL 31.42
  • Support Level
  • ANAB $15.40
  • DDL $2.10
  • Resistance Level
  • ANAB $19.82
  • DDL $2.43
  • Average True Range (ATR)
  • ANAB 1.49
  • DDL 0.19
  • MACD
  • ANAB 0.16
  • DDL -0.00
  • Stochastic Oscillator
  • ANAB 96.26
  • DDL 25.00

About ANAB AnaptysBio Inc.

AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, our PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, our BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).

About DDL Dingdong (Cayman) Limited (each two representing three)

Dingdong (Cayman) Ltd is the fastest growing on-demand e-commerce company in China. The company directly provides users and households with fresh produce, meat and seafood, and other daily necessities through a convenient shopping experience supported by an extensive self-operated frontline fulfillment grid. It recognizes revenues from product sales of fresh groceries and other daily necessities through Dingdong Fresh APP and mini-programs and membership services.

Share on Social Networks: